Hong Kong stock exchange data shows that on September 23, GENFLEET-B (02595) saw a position change, with a total transfer value of HK$912 million, accounting for 9.11% of its shares. A shareholder transferred 8.782 million shares into China International Capital Corporation Hong Kong Securities, while 24.5884 million shares were moved out of China Securities Depository and Clearing Corp.
GENFLEET-B issued an announcement stating that its board has noticed a recent rise in the company's share price and wishes to update shareholders and potential investors on the latest business developments. The company's clinical project GFH375, in combination with cetuximab, was listed for breakthrough therapy designation (BTD) by the Center for Drug Evaluation of China's National Medical Products Administration on September 18, 2026, for the treatment of KRAS G12D mutant metastatic colorectal cancer in patients who have failed prior oxaliplatin, fluoropyrimidine, and irinotecan-based chemotherapy. The application for this clinical project was submitted on August 13, 2026, with the public notice period ending on September 24, 2026.
The company originally planned to announce the formal inclusion of this clinical project in the BTD list according to market practice. However, in line with relevant provisions of the Listing Rules, the company is now announcing the review progress of the proposed inclusion in the BTD list at this stage. As there remains a potential risk that the project may not be approved after the public notice period, shareholders and potential investors should act with caution when trading or considering trading in the company's securities. Given this announcement, the company does not plan to proactively issue another announcement after the clinical project is formally included in the BTD list.
Comments